German economy ministry: We are in principle in favor of BioNTech/CureVac transaction; we will initiate usual review processes.

German economy ministry: We are in principle in favor of BioNTech/CureVac transaction; we will initiate usual review processes.

The German economy ministry has expressed its support for the proposed acquisition of CureVac by BioNTech, indicating a favorable stance towards the transaction. The ministry has stated that it is in principle in favor of the deal and will initiate the usual review processes [1]. This development comes amidst growing optimism about the potential benefits of the acquisition for both companies and the broader German economy.

The acquisition, valued at approximately $1.25 billion, is an all-stock transaction aimed at enhancing BioNTech's capabilities in mRNA-based cancer immunotherapy. The transaction is expected to close in 2025, subject to customary conditions and regulatory approvals [2]. The German Federal government and major CureVac shareholders, including dievini Hopp BioTech, have indicated their support for the acquisition, highlighting the strategic significance of the deal.

The German economy ministry's endorsement of the BioNTech/CureVac transaction aligns with the broader economic goals of the German government. The ministry's support underscores the potential for the acquisition to drive innovation and create long-term value in the German biotechnology sector. The acquisition is expected to complement BioNTech's existing capabilities and technologies, positioning the company to accelerate its oncology strategy.

In the context of the broader German economy, the acquisition is seen as a positive development. The German cabinet has recently approved a 46-billion-euro tax relief package and a 500-billion-euro infrastructure fund, which are expected to boost the German economy. The Ifo institute has raised its growth forecasts for the German economy for 2025 and 2026, citing these fiscal measures as a key factor in the expected growth spurt [3]. The BioNTech/CureVac acquisition is seen as a further boost to the German economy, given its potential to drive innovation and create jobs in the biotechnology sector.

The support of the German economy ministry for the BioNTech/CureVac acquisition highlights the strategic importance of the deal for the German economy. The ministry's endorsement of the transaction is a positive sign for investors and financial professionals, indicating the potential for the acquisition to drive innovation and create long-term value in the German biotechnology sector.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3SF0AK:0-ifo-institute-raises-german-growth-forecasts-due-to-new-government-plans/
[2] https://www.nasdaq.com/articles/biontech-acquire-curevac-strategic-move-advance-mrna-cancer-immunotherapy-initiatives